The Pakistan program for control of acute respiratory tract infections (ARIs) adopted the standard ARI-case-management strategy of the World Health Organization and recommended co-trimoxazole for the management of nonsevere pneumonia. Reports in that country of high in vitro antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae to co-trimoxazole prompted the program to reevaluate its treatment policy. Two community-based studies during 1991 -1993 showed in vivo efficacy of co-trimoxazole in 92% and 91% of children with nonsevere pneumonia. A third double-blind trial showed co-trimoxazole and oral amoxicillin to be equally effective in vivo in cases of nonsevere pneumonia, despite high in vitro resistance. Country-wide surveillance from 1991 to 1994 revealed 78.3% -79.9% in vitro resistance to co-trimoxazole among S. pneumoniae isolates and 59.5% -61.0% among H. influenzae isolates. Co-trimoxazole is still recommended by the Pakistan ARI control program. The fact that amoxicillin is three times more expensive and must be administered more frequently is a big impediment to recommending it as a first-line drug for nonsevere pneumonia.
Etiologic studies of acute lower respiratory tract infections mendations, the program considered the following factors. (1) There was no evidence that in vitro resistance to co-trimoxazole carried out in Pakistan during the late 1980s documented the important role of Streptococcus pneumoniae and Haemophilus resulted in failure of therapy in cases of nonsevere pneumonia.
(2) Amoxicillin, the alternative antibiotic, was 3 times more influenzae as the causative agents of pneumonia in hospitalized children [1 -4] . There were two important findings reported.
expensive and needed to be administered 3 times a day (instead of 2 times for co-trimoxazole). (3) Changing national recomFirst, there were very high rates of S. pneumoniae and H. influenzae bacteremia in children hospitalized with pneumomendations would mean retraining health care workers, which would be time-consuming, difficult, and expensive. nia. Second, a high proportion of these invasive isolates were resistant to co-trimoxazole [2 -4] . Forty-three percent of blood Prior to making a decision and because of concerns that the effectiveness of the national ARI control program might beisolates of H. influenzae and 31% of those of S. pneumoniae had reduced in vitro susceptibility to co-trimoxazole, with an come compromised because of increasing microbial resistance to co-trimoxazole, the program launched several focused ap-MIC of ú4 mg/L. In 1989 the government of Pakistan implemented a national acute respiratory infection (ARI) control plied-research projects. These included four studies of clinical efficacy as well as surveillance activities for documenting antiprogram based on the standard ARI-case-management guidelines of the World Health Organization (WHO) [5] . The promicrobial resistance patterns of S. pneumoniae and H. influenzae nasopharyngeal isolates. In one clinical efficacy study, antigram selected oral co-trimoxazole to treat outpatient nonsevere pneumonia.
microbial resistance patterns of S. pneumoniae and H. influenzae blood isolates were also tested. The objectives Pediatricians expressed concerns about the program's recommendation of co-trimoxazole for nonsevere pneumonia, beof these research activities were to document changes in the patterns of antimicrobial resistance of S. pneumoniae and cause of the reported resistance rates for H. influenzae and S. pneumoniae. In considering whether to change its recom-H. influenzae and to establish the relationship between in vitro resistance and clinical failure rates with ARI case management. The objective of this article is to review the data from Pakistan ARI studies and discuss the implications for national ARI This article is part of a series of papers presented at a symposium entitled control programs and future ARI research. ' NOTE. ARI Å acute respiratory infection; WHO Å World Health Organization. * The resistance level MIC was §1 mg/mg. † Only 242 nasopharyngeal isolates were tested by the disk-diffusion method; for co-trimoxazole, the resistance level (zone of inhibition) was õ10 mm. presented at scientific meetings for which abstracts were avail-
The second study, a double-blind, randomized, controlled able are included in this review. Unpublished data have been trial, was carried out in Islamabad/Rawalpindi during the reviewed with permission from authors.
1991 -1992 ARI season (October -April). It included children whose illness was diagnosed according to the WHO ARI diagnostic categories of nonsevere pneumonia (49.2%) and severe Results pneumonia (50.8%) [7] . One-hundred thirty-one children (22.0%) were bacteremic. Therapy failure in cases of nonsevere
Clinical Efficacy Studies
pneumonia was defined by oxygen saturation of õ87% for ú30 minutes when the child was calm; prolonged tachypnea Four clinical studies conducted from 1991 to 1996 have been when calm (a respiratory rate of ú20 above the age-specific summarized in table 1. All these studies primarily used the WHO cut-off point for 2 hours); chest indrawing; convulsions, ARI diagnostic categories developed by the WHO for standard drowsiness, inability to drink, and/or stridor at rest; either lack ARI-case management [5] . The first study was conducted over of improvement or deterioration clinically, in the opinion of the a 4-month period in rural Islamabad, where special clinics were senior pediatrician; and death. For severe pneumonia, therapy established, and all children with ARI during that period were failure was defined by all of the above except chest indrawing. followed up at the clinics or at home [6] . For a further 18
The therapy failure rate was the proportion of enrolled children children (3.7% of 491) assessed initially as not having pneumowho required a change of therapy while in the hospital, had a nia, pneumonia was diagnosed on follow-up visits, and they recurrence of pneumonia symptoms within 1 week of discharge were successfully treated with co-trimoxazole. from the hospital, or died. Clinical failure was defined by the following factors: the The clinical failure rate with co-trimoxazole for nonsevere respiratory rate did not improve after 48 hours of treatment; pneumonia was 13.3%, whereas for severe pneumonia it was breathing became more difficult or faster; or one or more 32.5%. Only one child (0.17%) died. There was no significant of the following was noted: chest indrawing, inability to difference in the treatment outcome by drug in nonsevere pneudrink, convulsions, stridor in a calm child, abnormal sleepimonia cases. A subanalysis of 89 bacteremic patients who ness, and death. The clinical failure rate was defined as the received co-trimoxazole showed that of 54 H. influenzae -innumber of children needing a change of therapy or dying, fected patients, 29 had nonsevere and 25 had severe pneumonia; among those who had WHO-defined nonsevere pneumonia of 35 S. pneumoniae -infected patients, 17 had nonsevere and at the time of initial assessment. The clinical failure rate 18 had severe pneumonia. The therapy failure rate among pawas only 8 The data from a pharmacokinetic study of co-trimoxazole in children suggested that a higher dose of oral co-trimoxazole clinical success rate [10] . In an outpatient-based, multicenter, double-blind, randomized trial, a standard dose of trimethoprim (4 mg/kg, twice a day) or a double dose (8 mg/kg) was adminisstudies has been negligible. However, the Pakistan ARI control program has been criticized for not changing its recommendatered to an equal number of children with community-acquired nonsevere pneumonia [11] . Clinical failure was defined when, tions from co-trimoxazole to amoxicillin, in light of the high in vitro resistance and increase in failure of therapy in vivo. after 2 days, the respiratory rate was the same (£5) as at the time of initial assessment; the respiratory rate had increased Before the antibiotic-change recommendation is discussed, the limitations of the studies summarized in the results sections (ú5); and/or one or more of the following occurred: chest indrawing, convulsions, drowsiness, inability to drink, stridor need to be addressed. First, only two clinical trials were randomized, controlled studies; the other two were open studies. at rest, and death. For 80% of the enrolled children therapy did not fail, but no significant difference was observed between However, community studies done in this manner are useful, as they are closer to the real situation. Second, in all the studies the two therapeutic regimens. Only one child (0.01%) died. a very good follow-up of patients was managed, but this might not be possible in reality. This might result in a situation in Antimicrobial Resistance Surveillance which a patient with nonsevere pneumonia whose therapy with oral co-trimoxazole fails may become sicker and die at home. In vitro resistance levels (as reflected by MICs) of S. pneumoniae and H. influenzae are summarized in table 2. There were Although this hypothetical situation is quite possible, data show that when a child becomes sicker or doesn't get better in 2 -3 high levels of resistance of both organisms to co-trimoxazole: 78.3% in 1991 -1992 (A. Kumar, personal communication) days, the parents or guardians seek immediate health care [13, 14] . and 79.9% in 1993 -1994 for S. pneumoniae ([12] and A. Kumar, personal communication) and 61.0% in 1991 -1992 Third, although the basic criteria for therapy failure in all studies were based on the WHO standard ARI-case-manageand 59.5% in 1993 -1994 for H. influenzae. There was relatively less resistance of S. pneumoniae to penicillin: 27.3% in ment guidelines, there were subtle differences between the criteria. In particular, the hospital-based study used more sensitive 1991 -1992 and 51.5% in 1993 -1994. criteria for clinical therapy failure [7] . This might have resulted in the categorizing of more cases as therapy failures.
Discussion
In the antimicrobial resistance surveillance studies, there were a couple of limitations. First, the number of isolates lost Over a period of 8 years the clinical therapy failure rate with co-trimoxazole increased from 8.4% to 20%. Fortunately, this during transport between the isolation site/regional laboratories and the reference laboratories (where susceptibility was tested) condition was adequately treated by a second-line antibiotic (oral amoxicillin), and the mortality rate for pneumonia in these might have resulted in a bias. Second, the surveillance results / 9c61$$fe38 01-20-99 13:25:47 cida UC: CID are for nasopharyngeal isolates, which may have greater resistwo times a day for co-trimoxazole; this might lead to poor compliance. Third, in 8 years, 3,000 physicians and 34,000 tance levels than invasive isolates.
The data from these studies can be interpreted in different CHWs have been trained in standard ARI case management; retraining them all is going to be logistically difficult, very ways. First, low clinical failure rates for nonsevere pneumonia may be explained by low sensitivity of the WHO criteria for expensive, and time-consuming. Fourth, at present there are no data showing that clinical failure with co-trimoxazole is reidentifying cases of bacterial pneumonia. Alterations in the WHO classification need to be considered to improve specificsulting in a higher mortality. Nearly all cases in which clinical failure of co-trimoxazole occurred were successfully treated ity for identifying cases of bacterial pneumonia. Second, achievable blood and lung levels of co-trimoxazole may be with oral amoxicillin. Although the above-mentioned reasons justify the Pakistan high enough to effectively treat pneumonia, despite in vitro resistance. This means that in vitro resistance does not correlate ARI program's decision not to change the first-line antibiotic, a couple of issues like failure to follow up and missed opportuwith in vivo failures in cases of nonsevere pneumonia.
Third, we can try to predict the percentage of resistance from nities need to be addressed. The condition of a child with nonsevere pneumonia not responsive to oral co-trimoxazole, if the clinical failure rate. Following is a hypothetical analysis. For example, for cases of nonsevere pneumonia, one can estinot followed up or assessed properly at follow-up, may progress to severe pneumonia and possibly death. mate that probably 40% of the cases will be bacterial pneumonia with S. pneumoniae and H. influenzae. If one assumes that Some factors that may have led to high in vitro antimicrobial resistance and increased in vivo failure of therapy for pneumo-33% of the isolates are resistant, the failure rate associated with co-trimoxazole would be 13.2%. One could refine this nia need discussion. First is the increasing use of antibiotics, particularly co-trimoxazole, in Pakistan. A study in a major city analysis a bit by saying that 70% of the 40% of cases of pneumonia that are bacterial are due to S. pneumoniae with a in Punjab showed that 43% of general-practice prescriptions for treatment of cough and cold episodes included an injectable 33% rate of resistance to co-trimoxazole, while the other 30% of bacterial pneumonia cases are due to H. influenzae with a antibiotic and 83% included an oral antibiotic [16] . In a couple of hospitals, more than 80% of prescriptions for ARI included 40% rate of resistance. Analysis reveals a failure rate of 14%.
Given the fact that from 1991 to 1995 -1996 the clinical antibiotics, and co-trimoxazole was the most commonly prescribed antibiotic. failure rate increased from 8.4% to 20.0% (table 1) , and if one assumes again that 40% of the cases of nonsevere pneumonia A couple of other studies have reported that antibiotics were included in 53% [17] and 57% [18] of all prescriptions for are bacterial in nature, it is possible to calculate the projected proportion of resistance. This means 0.4 1 proportion of resischildhood illnesses. There is some evidence that CHWs have a tendency to overprescribe co-trimoxazole and to use it in tance equals the clinical failure rate. For 1991 the proportion of resistance would be estimated at 21%. Similarly, in 1995, inappropriate doses and durations [19] . Besides misuse by health care workers, antibiotics are also easily available over 0.4 1 proportion of resistance strains equals 0.2, for a 50% rate of resistance. This analysis suggests that the clinical failure the counter and are self-prescribed by the public. The Pakistan ARI control program has taken a few steps rates correlate with the observed proportion of bacterial strains that are resistant. However, it seems that the bacteremic patients to address the issue of antibiotic misuse. First is coordination with the national essential drugs program and nongovernmenwho have severe pneumonia are more likely to fail to respond to therapy, even if they have relatively susceptible organisms.
tal organizations to promote rational use of drugs. Second is a 3-day training program for general practitioners. Third is The Pakistan ARI program cited several reasons for not changing the first-line antibiotic therapy for nonsevere pneumonia, after having trained physicians visit general practitioners in their clinics/surgery to promote standard ARI case management. these study results were available. First, Pakistan is a large country with a big population (140 million) [15] . It is estimated that 22
Finally, the program is working with the Pakistan CHW program to improve supervision of CHWs and to retrain them million episodes of pneumonia occur each year in the population of children õ5 years old. Only 2%-3% have severe pneumonia; when necessary. the rest have nonsevere pneumonia that responds well to oral antibiotics and can be managed at home. The estimated cost (in Conclusions and Recommendations United States dollars) for just antibiotic therapy (at a hypothetical weight of 10 kg) for all pneumonia episodes in children would be First, it is clear that despite high rates of in vitro antimicrobial resistance, the rates of in vivo response of ambulatory as follows: oral co-trimoxazole, $7.7 million; oral amoxicillin, $25.3 million; and oral co-trimoxazole for all nonsevere pneumopneumonia to the first-line antibiotic (co-trimoxazole) were acceptable to the Pakistan national ARI control program. Alnia children, with a 20% therapy failure rate and a change to amoxicillin therapy, $12.8 million. The total health budget for though co-trimoxazole is still being used in most developing countries for treatment of ambulatory pneumonia, very few Pakistan at present is only $66 million.
Second, besides being three times more expensive, amoxicilcountries have antimicrobial resistance and clinical efficacy data from their own setting. Simple methodology and tools are lin requires administration three times a day, rather than the / 9c61$$fe38 01-20-99 13:25:47 cida UC: CID
